NCT05528705

Investigator Initiated Trial to Evaluate Efficacy and Safety of LAENNEC (Human Placenta Hydrolysate) Administered by Ultrasonography Guided Subacromial Bursa Injection in Patients With Shoulder Impingement Syndrome

A Randomized, Parallel-group, Placebo-controlled, Single-blind, Investigator Initiated Trial to Evaluate Efficacy and Safety of LAENNEC (Human Placenta Hydrolysate) Administered by Ultrasonography Guided Subacromial Bursa Injection in Patients With Shoulder Impingement Syndrome

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Green Cross Wellbeing · Industry
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To patients with shoulder collision syndrome, LAENNEC (Human Placenta Hydrolysate) is administered as an injection in the ultrasonic induction underglone, to evaluate the effectiveness and safety.

Conditions

• Shoulder Impingement Syndrome

Interventions

Type	Name	Description
BIOLOGICAL	LAENNEC	Subacromial spatial administration
OTHER	0.9% normal saline	Subacromial spatial administration

Timeline

• Start date: 2022-09-13
• Primary completion: 2023-10-23
• Completion: 2024-01-31
• First posted: 2022-09-06
• Last updated: 2026-02-24

Locations

3 sites across 1 country: South Korea